CustomersYachts
11.1K posts

CustomersYachts
@Michaelrose102
Everything comes and goes, may as well trade some paper while we’re at it… Anything about stocks is not advice



Some really interesting commentary on DOE to NRC licensing from @oklo $OKLO during their earnings call: "We're expecting the NRC to fairly soon issue basically their approach, if you will, for converting a DOE-authorized and built and operating facility to an NRC licensed facility. We're in a great spot to be able to, you know, go through that and experience what that looks like. That inherently is not like a COLA because you're not getting a license to build and operate the plant. The plant's already built. It's really a conversion process, which is cool. They have to do the safety review, and they have to reference and leverage everything before."

Beijing is urging peace talks in the Middle East. Chinese Foreign Minister Wang Yi held a phone call with Iranian Foreign Minister Abbas Araghchi on Tuesday, calling for an immediate start to negotiations and an end to hostilities caixinglobal.com/2026-03-24/chi…

I’ve made $AVR a decent size position. Some short personal assumption from my POV🧵; •enrollment q1 ‘27 - pivotal readout h1 28 •market gets to 65-75% POS •Model mrkt share - quick ramp in small annuli to 35% & general 5-10% •if MDT buys post paradigm - $4b price tag floor






Some interesting comments from Jacob Van Naarden, $LLY head of business development, at STAT's Breakthrough Summit East event yesterday: On deal volume: Jake, himself, is seeing approx 10 deals per week, ie deals that are important enough, or diligenced enough, to cross his desk. "We are making more offers than you can possibly imagine. Either me personally or members of my team are making between three and five offers a week to either license something or buy a company or do some kind of discovery deal. Of course, you haven't read about all those because they don't all end up happening..." Why don't all these deals get done? A lot of deals are small, or involve private companies or preclinical assets, are not press released, etc etc... However, when it comes to public company deals... Jake: "What's interesting is how many of the multi-billion dollar deals we are attempting to do, and sort of get rebuffed with some frequency..." He added... "We engage with a lot of publicly traded companies... and those are the ones where I'm particularly surprised you put sort of a market premium offer on the table, and you're not even granted a conversation, so to speak, as you have a conversation, but it sort of doesn't go anywhere. That's pretty surprising, and that's that's happening more frequently than I would have expected."

$AVR Pretty asymmetric set up - albeit with a decent time horizon. ADAR1 involved as well. I picked up shares @Se19edy @A_May_MD @EricTheUmpire

I’ve made $AVR a decent size position. Some short personal assumption from my POV🧵; •enrollment q1 ‘27 - pivotal readout h1 28 •market gets to 65-75% POS •Model mrkt share - quick ramp in small annuli to 35% & general 5-10% •if MDT buys post paradigm - $4b price tag floor










